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Reactions of [5+1]-cyclocondensation of [2-(3-aryl-1H-1,2,4-triazol-5-yl)phenyl]amines with aliphatic and aroma- 
tic aldehydes produce the corresponding 5-R-2-aryl-5,6-dihydro- or 5-R-2-aryl-[1,2,4]triazolo[1,5-с]quinazolines 
depending on the conditions. The optimal conditions of the reaction have been found, and factors contributing 
to oxidation of 5-R-2-aryl-5,6-dihydro-[1,2,4]triazolo[1,5-с]quinazolines have been determined. The alterna-
tive synthetic approaches for 5-R-2-aryl-[1,2,4]triazolo[1,5-с]quinazolines, namely oxidation of their reduced 
analogues and interaction of [2-(3-aryl-1H-1,2,4-triazol-5-yl)phenyl]amines with acylhalides of aliphatic or aro-
matic carboxylic acid have been proposed. Purity and the structure of the compounds synthesized have been 
confirmed by the complex of physicochemical methods, including LC-MS, 1H-, 13C NMR, mass-spectrometry and 
elemental analysis. The peculiarities and differences of 1H- and 13C-NMR spectral patterns of 5-R-2-aryl-5,6-
dihydro-[1,2,4]triazolo[1,5-с]quinazolines and their aromatic analogues have been described.
5,6-ДигіДро-[1,2,4]триазоло[1,5-с]хіназоліни. ПовіДомлення 1. особливості ПовеДінки [2-(3-арил- 
1H-1,2,4-триазол-5-іл)феніл]амінів в реакціях з альДегіДами аліфатичного та ароматичного ряДу
с.в.холодняк, к.П.Шабельник, O.Ю.воскобойнік, г.г.берест, с.I.коваленко
ключові слова: [2-(3-арил-1H-1,2,4-триазол-5-іл)феніл]аміни; [5+1]-циклоконденсація; спектральні харак-
теристики
Реакції [5+1]-циклоконденсації [2-(3-арил-1H-1,2,4-триазол-5-іл)феніл]амінів з альдегідами аліфатично-
го та ароматичного ряду в залежності від умов проведення перебігають з утворенням 5-R-2-арил-
5,6-дигідро- або 5-R-2-арил-[1,2,4]триазоло[1,5-с]хіназолінів. Визначені оптимальні умови реакції та 
встановлені основні фактори, які сприяють окисненню 5-R-2-арил-5,6-дигідро-[1,2,4]триазоло[1,5-с]
хіназолінів. Розроблені методи зустрічного синтезу 5-R-2-арил-[1,2,4]триазоло[1,5-с]хіназолінів: окис-
ненням їх гідрованих аналогів або взаємодією [2-(3-арил-1H-1,2,4-триазол-5-іл)феніл]амінів з хлорангі-
дридами відповідних алкіл(арил)карбонових кислот. Індивідуальність та будова синтезованих сполук 
підтверджена хроматомас-, 1Н-, 13С-ЯМР-спектрами та елементним аналізом. Показані особливості 
та відмінності резонування характеристичних протонів 5-R-2-арил-5,6-дигідро-[1,2,4]триазоло[1,5-с]хі-
назолінів та їх ароматичних аналогів.
5,6-ДигиДро-[1,2,4]триазоло[1,5-с]хиназолины. сообщение 1. особенности ПовеДения [2-(3-арил-1H- 
1,2,4-триазол-5-ил)фенил]аминов в реакциях с альДегиДами алифатического и ароматического ряДа
с.в.холодняк, к.П.Шабельник, а.Ю.воскобойник, г.г.берест, с.и.коваленко
ключевые слова: [2-(3-арил-1H-1,2,4-триазол-5-ил)фенил]амины; [5+1]-циклоконденсация; спектраль-
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Реакции [5+1]-циклоконденсации [2-(3-арил-1H-1,2,4-триазол-5-ил)фенил]аминов с алифатическими и 
ароматическими альгегидами в зависимости от условий проведения образуют 5-R-2-арил-5,6-дигидро- 
или 5-R-2-арил-[1,2,4]триазоло[1,5-с]хиназолины. Определены оптимальные условия реакции и уста-
новлены основные факторы, способствующие окислению 5-R-2-арил-5,6-дигидро-[1,2,4]триазоло[1,5-с]
хиназолинов. Разработан встречный синтез 5-R-2-арил-[1,2,4]триазоло[1,5-с]хиназолинов: окислением 
их гидрированных аналогов или взаимодействием [2-(3-арил-1H-1,2,4-триазол-5-ил)фенил]аминов 
с хлорангидридами соответствующих алкил(арил)карбоновых кислот. Индивидуальность и строение 
синтезированных соединений подтверждены хроматомас-, 1Н-, 13С-ЯМР-спектрами, элементным ана-
лизом. Показаны особенности и отличие резонирования характеристических протонов 5-R-2-арил-
5,6-дигидро-[1,2,4]триазоло[1,5-с]хиназолинов и их ароматических аналогов.Ever-growing interest in quinazoline derivatives [1, 2] as potential bioactive agents also attracts at- tention of the specialists in medicinal chemistry, espe- cially to the condensed derivatives of the heterocy-clic system mentioned above, in particular to [1,2,4]triazolo[с]quinazolines. It should be noted that ac- cording to the published papers the potential of hete- roannelated quinazolines is not limited by their high biologic activity [3-5]. Moreover, these compounds 
are also the study objects in chemistry of materials [6, 7] and chemistry of complex compounds [7]. Among the known methods suitable for the synthesis of the [1,2,4]triazolo[с]quinazoline system, the most used are: domino-reactions that leading to the simultane-ous formation of quinazoline and triazole cycles, annu-lation of the triazole fragment to the quinazoline sys-tem and formation of the pyrimidine fragment based 
on modification of 2-(1H-1,2,4-triazol-5-yl)anilines 
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ISSN 2308-8303[1, 8]. It is important that the last-mentioned ap-proach has advantages when it is necessary to vary the nature of a substituent in position 5 and satura-tion of the pyrimidine fragment. In spite of the fact that methods of the synthesis for [1,2,4]triazolo[с]quinazoline systems via interaction of substituted 
2-(1H-1,2,4-triazol-5-yl)anilines with electrophiles are known [7, 9], the objects of most studies pub-lished are target compounds and their properties, but not the [5+1]-cyclocondensation process and its peculiarities.Considering the abovementioned facts we deci- 
ded to study the interaction of [2-(3-aryl-1H-1,2,4-triazole-5-yl)phenyl]amines with carbonyl-contain-
ing compounds, as well as to determine the influence of their structure, the nature of solvents and the re-action conditions on the products’ structure.
Results and Discussion To improve the role of [5+1]-cyclocondensation processes in the synthesis of the triazolo[c]quinazo- 
line system, [2-(3-aryl-1H-1,2,4-triazole-5-yl)phenyl] amines [10, 11] as 1,5-binucleophiles were used 
(1.1-1.9). It was found that interaction of these ami- nes with aromatic and aliphatic aldehydes in the ace- tic acid medium for 3-6 h led to formation of the mix- ture of products. According to spectral data the com- ponents of this mixture were 5-R-2-aryl-5,6-dihyd- ro-[1,2,4]triazolo[1,5-с]quinazolines (2) and their aro- 
matic analogues (3) in the ratio of 2:1. Further in-crease in the reaction duration more than 8 h in most cases led to the quantitative oxidation of the corre-sponding dihydroderivatives into 2-aryl-5-R-[1,2,4] triazolo[1,5-c]quinazolines (3.1-3.14) [10]. The most 
significant factors contributing to oxidation of com-
pounds 2 are a significant duration of the reaction and high temperature. The experimental data has shown that compounds 
2.1-2.18 may be obtained with excellent yields via 
refluxing the initial compounds mentioned above for 2-4 h in alcohols in the presence of an acidic cata-lyst, as well as with stirring in the same solvent at ambient temperature and under the atmosphere of for 24 h. It should be noted that this reaction may be performed in other solvents that are inert in rela-
tion to the initial substances (methanol, propanol-2, propanol-2, dioxane, acetic acid), but the inert atmo-sphere is the necessary condition.Considering formation of compounds 2 it pro-ceeded as double nucleophilic addition, wherein the corresponding Schiff base played the role of an in- termediate. Further cyclisation progressed as a non- stereoselective transformation and yielded the race- mic mixture of 5-R(S)-(alkyl-, cycloalkyl-, aryl-)-2-aryl- 5,6-dihydro[1,2,4]triazolo[1,5-с]quinazolines (2.1-2.18). For unequivocal evidence of the oxidation pro- cess 2-aryl-5-R-[1,2,4]triazolo[1,5-c]quinazolines were prepared according to two alternative protocols. The 
first approach was based on oxidation of compounds 
2.1, 2.2, 2.4, 2.8 and 2.10 with bromine or potas-
sium permanganate (Scheme). Compounds 3.8, 3.9 and 3.12 were obtained via reflux of anilines 1.1 and 
1.8, acylhalides of the corresponding aliphatic and aromatic carboxylic acid and the equimolar quantity 
of sodium acetate in acetic acid (Scheme). The reac-tion proceeded as a phased reaction that included acylation followed by cyclisation of the N-acyl de-rivative formed.Purity and the structure of the compounds syn-
thesized were confirmed by the complex of physico- 
Scheme
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ISSN 2308-8303chemical methods, including LC-MS, 1H NMR, 13C NMR-, mass-spectrometry and elemental analysis. In LC-MS spectra of all compounds synthesized the high-inten- sive signals of quasi-molecular ions with the proper molecular weight were detected.The formation of compounds 2.1-2.18 was pro- ven by the presence of H-6 signals in 1H NMR – spec-tra at the 7.65-6.90 ppm. For compounds 2.6-2.18 the signals mentioned overlapped with multiplets of 
the aryl moiety in position 5. Signals of Н-5 in 1H NMR spectra of compounds formed as a result of interaction between the initial anilines and aliphatic aldehydes 
2.1-2.5 were observed as broad triplets or multi-plets at 5.79-5.60 ppm. At the same time compounds containing the aromatic moiety in position 5 were characterized by the H-5 singlet at 7.16-6.93 ppm. Additionally 1H NMR-spectra in CDCl3 were registe- red for compounds 2.6 and 2.10. It was shown that signals of H-5 and H-6 were observed as singlets at 5.48 ppm and the 4.76 ppm, respectively. The protons of heterocyclic fragments were reg-
istered as sequentially located doublets Н-10 (7.99-
7.72 ppm) and Н-7 (6.92-6.76 ppm) and triplets of 
Н-8 (7.83-7.16 ppm), Н-9 (6.98-6.72 ppm). Signals of substituents at positions 2 and 5 had chemical shifts that were in compliance with their structure [12].At the same time 1H NMR-spectra of compounds 
3.1-3.14 differed significantly from spectra of the re- 
duced analogues. The signals of Н-10, Н-9, Н-8 and 
Н-7 were observed in much more lower field. The signals of H-10 registered at 8.58-8.49 ppm were the 
most shifted in low field.In 13С NMR-spectra of compounds 2.10, 3.13, 
3.14 the signals of C5 were the most characteristic. Thus, for compound 2.10 the signal mentioned was registered at 67.11 ppm, but for 3.13 and 3.14 – at 147.26 ppm and 148.15 ppm, respectively, indicating the different hybridization state of carbon. 
The spectral characteristics definitely proved the structure of both 6,7-dihydro-[1,2,4]triazolo[1,5-c]quinazoline system and their aromatic analogues.
Experimental Part Melting points were determined in open capillary tubes and were uncorrected. The elemental analyses 
(C, H, N, S) were performed using an ELEMENTAR 
vario EL Cube analyzer (USA). Analyses were indica- ted by the symbols of the elements or functions within ±0.3% of the theoretical values. 1H NMR spec-
tra (400 MHz) and 13C NMR spectra (100 MHz) were 
recorded on a Varian-Mercury 400 (Varian Inc., Palo Alto, CA, USA) spectrometer with TMS as an internal standard in DMSO-d6 solution. LC-MS were recor- ded using the chromatography/mass spectrometric system consisting of an “Agilent 1100 Series” high per-
formance liquid chromatograph (Agilent, Palo Alto, CA, USA) equipped with a diode-matrix and an “Agi-
lent LC/MSD SL” mass-selective detector (atmosphe- ric pressure chemical ionization – APCI).Synthetic procedures were conducted according to the commonly used approaches for the synthesis of prospective bioactive agents. All reagents were com- 
mercially available (“Sigma-Aldrich”, Missouri, USA and “Enamine”, Kiev, Ukraine) and used without ad-
dition purification. 2-(3-Aryl-1Н-1,2,4-triazole-5-yl)
phenyl]amines (1.1-1.9) were obtained according to the synthetic protocols described [10, 11]. 
the general method for the synthesis of 5-r1- 
2-aryl-5,6-dihydro[1,2,4]triazolo[1,5-c]quinazo- 
lines (2.1-2.18). Add 10 mmol of aromatic or alipha- tic aldehyde to the solution of 10 mmol of the corre- sponding {2-[3-aryl-1H-1,2,4-triazolo-5-yl]phenyl}ami- 
ne (1.1-1.9) in 10 ml of glacial acetic acid or 10 ml of propanol-2. When using propanol-2 as a solvent add two drops of sulphuric or hydrochloric acid. Re-
flux the mixture obtained for 2 h or stir at ambient temperature for 24 h in the atmosphere of nitrogen. Then cool the mixture and pour into the saturated solution of sodium acetate. Filter the precipitate for- 
med and dry. In case of insufficient purity recrystal-lize the compounds obtained from methanol.
The compounds (2.1-2.18) synthesized are white crystalline powders, insoluble in water, soluble in al-cohols, dioxane and DMF.
5-Isopropyl-2-(3-methoxyphenyl)-5,6-dihydro 
[1,2,4]triazolo[1,5-c]quinazoline (2.1). Yield – 40.9%. M.p. – 184-186°C; 1H NMR (400 MHz, dmso_d6) δ 7.99 
(d, J = 8.2 Hz, 1H, H-10), 7.83 (t, J = 7.9 Hz, 1H, H-8), 7.32-
7.12 (m, 2H, H-5 PhOCH3-3, H-6), 7.16 (m, 2H, H-2,6 PhOCH3-3), 6.91 (d, J = 9.9 Hz, 1H, H-4 PhOCH3-3), 
6.86 (d, J = 8.0 Hz, 1H, H-7), 6.71 (t, J = 7.4 Hz, 1H, 
H-9), 5.71 (m, J = 3.5 Hz, 1H, H-5), 3.88 (s, 3H, -OCH3), 
2.40 (m, 1H, – CH(CH3)2), 1.03 (d, J = 6.9 Hz, 3H, – CH(CH3)2), 
0.90 (d, J = 6.8 Hz, 3H, - CH(CH3)2); LC-MS, m/z = 321 [M+1], 322 [M+2]; Anal. calcd. for C19H20N4O: C, 71.23; 
Н, 6.29; N, 17.49; Found: C, 71.26; Н, 6.31; N, 17.52.
5-Isobutyl-2-(3-fluorophenyl)-5,6-dihydro[1,2,4]
triazolo[1,5-c]quinazoline (2.2). Yield – 40.9%. M.p. – 129-131°C; 1H NMR (400 MHz, dmso_d6+ССl4) δ 7.92 
(d, J = 7.3 Hz, 1H, H-10), 7.79 (t, J = 7.5 Hz, 1H, H-8), 
7.45 (m, 2H, H-2,6 PhF-3), 7.19 (m, 1H, H-5 PhF-3), 
7.11 (t, J = 7.8 Hz, 1H, H-9), 6.92 (s, 1H, H-6), 6.87 
(d, J = 7.8 Hz, 1H, H-7), 6.78 (m, 1H, H-4 PhF-3), 5.79 
(m, 1H, H-5), 2.02 (m, 1H, -СН2СН(СН3)2), 1.57 (d, J = 6.0 Hz, 1H, -СН2СН(СН3)2), 1.13 (d, J = 5.3 Hz, 6H, 
-СН2СН(СН3)2); LC-MS, m/z = 323 [M+1], 324 [M+2]; Anal. calcd. for C19H19FN4: C, 70.79; Н, 5.94; N, 17.38; 
Found: C, 70.76; Н, 5.91; N, 17.33.
5-Cyclopropyl-2-phenyl-5,6-dihydro[1,2,4]triazolo 
[1,5-c]quinazoline (2.3). Yield – 41.6%. M.p. – 157-159°C; 1H NMR (400 MHz, dmso_d6+ССl4) δ 8.11 (d, J = 7.5 Hz, 2H, H-2,6 Ph), 7.87 (d, J = 7.3 Hz, 1H, H-10), 
7.53-7.49 (m, 1H, H-8), 7.49-7.36 (m, 3H, H-3, 5 Ph, 
H-6), 7.36-7.29 (m, 1H, H-4 Ph), 6.91 (t, J = 7.5 Hz, 
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1H, H-9), 6.80 (d, J = 7.9 Hz, 1H, H-7), 5.60 (m, J = 5.8 Hz, 1H, H-5), 3.69-3.60 (m, 1H, H-2 cyclopropyl), 
3.60-3.51 (m, 1H, Н-3 cyclopropyl), 2.83-2.71 (m, 
1H, Н-1 cyclopropyl), 2.30-2.13 (m, 2H, H-2, 3 cyclo-propyl); LC-MS, m/z = 289 [M+1], 290 [M+2]; Anal. calcd. for C18H16N4: C, 74.98; Н, 5.59; N, 19.43; Found: 
C, 75.01; Н, 5.62; N, 19.45.
5-Cyclohexyl-2-phenyl-5,6-dihydro[1,2,4]triazolo 
[1,5-c]quinazoline (2.4). Yield – 61.8%. M.p. – 196-198°C; 1H NMR (400 MHz, dmso_d6+ССl4) δ 8.12 (d, J = 7.5 Hz, 2H, H-2,6 Ph), 7.72 (d, J = 7.8 Hz, 1H, H-10), 
7.48-7.36 (m, 4H, H-3, 4, 5 Ph, H-6), 7.16 (t, J = 7.5 Hz, 
1H, H-8), 6.84 (t, J = 7.8 Hz, 1H, H-9), 6.76 (d, J = 7.9 Hz, 
1H, H-7), 5.66 (bs. t, 1H H-5), 2.38 (d, J = 12.7 Hz, 2H, 
H-3,5 cyclohexyl), 2.22 (d, J = 12.7 Hz, 2H, H-3,5 cyc- 
lohexyl),), 1.98-1.75 (m, 4H, H-2,6 cyclohexyl), 1.70-
1.75 (m, 1H, H-1 cyclohexyl), 1.24-1.11 (m, 3H, H-4 cyclohexyl); LC-MS, m/z = 331 [M+1]; Anal. calcd. for C21H22N4: C, 76.33; Н, 6.71; N, 16.96; Found: C, 76.35; 
Н, 6.74; N, 17.01.
2-(3-Methoxyphenyl)-5-cyclohexyl-5,6-dihydro 
[1,2,4]triazolo[1,5-c]quinazoline (2.5). Yield – 71.3%. M.p. – 176-177°C; 1H NMR (400 MHz, dmso_d6) δ 7.82 
(d, J = 7.8 Hz, 1H, H-10), 7.66 (d, J = 7.2 Hz, 1H, H-6 PhOCH3-3), 7.60 (s, 1H, H-2 PhOCH3-3), 7.32 (t, J = 8.1 Hz, 1H, H-5 PhOCH3-3), 7.16 (t, J = 7.5 Hz, 1H, H-8), 
6.90 (m, 2H, H-6, H-9), 6.85 (d, J = 7.9 Hz, 1H, H-7), 
6.72 (t, J = 7.3 Hz, 1H, Н-9), 5.69 (m, 1H, Н-5), 3.94 
(s, 3H, -OCH3), 1.71-1.51 (m, 4H, H-3,5 cyclohexyl), 
1.53-1.34 (m, 4H, H-2,6 cyclohexyl), 1.24 (m, 3H, H-1, 4 cyclohexyl); LC-MS, m/z = 361 [M+1]; Anal. calcd. for C22H24N4O: C, 73.31; Н, 6.71; N, 15.54; Found: C, 
73.34; Н, 6.74; N, 15.57.
2,5-Diphenyl-5,6-dihydro-[1,2,4]triazolo[1,5-c]quina- 
zoline (2.6). Yield – 98.7%. M.p. – 175-177°C; NMR 
(400 MHz, dmso_d6+ССl4) δ 8.05 (d, J = 7.3 Hz, 2H, 
H-2,6 2-Ph), 7.80 (d, J = 7.5 Hz, 1H, H-10), 7.65 (t, 1H, 
H-4 2-Ph), 7.52 (t, 1H, H-4 5-Ph), 7.47-7.31 (m, 7H, 
H-3,5 2-Ph, H-2,3,5,6 5-Ph, H-6,), 7.21 (t, J = 7.1 Hz, 1H, 
H-8), 6.93-6.75 (m, 3H, H-5,7,9); 1H NMR (400 MHz, CDCl3) δ 8.20 (d, J = 6.8 Hz, 2H, H-2,6 Ph), 8.01 (d, J = 7.6 Hz, 1H, H-10), 7.53 (m, 2H, H-4 2-Ph, H-4 5-Ph), 
7.45-7.40 (m, 6H, H-3,5 2-Ph, H-2,3,5,6 5-Ph), 7.34 
(t, J = 7.4 Hz, 1H, H-8), 6.98 (t, J = 7.4 Hz, 1H, H-9), 
6.84 (d, J = 7.9 Hz, 1H, H-7), 6.35 (s, 1H, H-5), 5.48 (s, 1H, H-6); LC-MS, m/z = 325 [M+1]; Anal. calcd. for C21H16N4: C, 77.76; Н, 4.97; N, 17.27; Found: C, 77.73; 
Н, 4.94; N, 17.24.
2-Phenyl-5-(2-hydroxyphenyl)-5,6-dihydro- 
[1,2,4]triazolo[1,5-c]quinazoline (2.7). Yield – 98.2%. M.p. – 170-172°C; 1H NMR (400 MHz, dmso_d6+ССl4) 
δ 8.01 (t, J = 6.3 Hz, 1H, H-2,6 Ph), 7.81 (d, J = 7.3 Hz, 
1H, H-10), 7.44-7.30 (m, 3H, H-3,4,5 Ph), 7.30-7.09 
(m, 6H, H-3,4,5,6 2-HOPh, H-6, H-8), 7.02 (s, 1H, H-5), 
6.85 (d, J = 7.6 Hz, 1H, H-7), 6.80 (t, 7.4 Hz 1H, H-9), 
2.50 (d, J = 1.1 Hz, 1H, -OH); LC-MS, m/z=341 [M+1]; Anal. calcd. for C21H16N4O: C, 74.10; Н, 4.74; N, 16.46; 
Found: C, 74.07; Н, 4.70; N, 16.42.
2-Phenyl-5-(2-(trifluoromethyl)phenyl)-5,6-dihydro- 
[1,2,4]triazolo[1,5-c]quinazoline (2.8). Yield – 96.9%. M.p. – 190-191°C; 1H NMR (400 MHz, dmso_d6+ССl4) 
δ 8.00 (d, J = 7.5 Hz, 2H, H-2,6 Ph), 7.86 (d, J = 7.5 Hz, 1H, H-3 2-CF3Ph), 7.80 (d, J = 7.3 Hz, 1H, H-10), 7.69- 
7.53 (m, 3H, H-3,4,5 Ph), 7.36 (m, 4H, H-4,5,6 2-CF3Ph, 
H-6), 7.23 (t, J = 7.6 Hz, 1H, H-8), 7.11 (s, 1H, H-5), 
6.94-6.79 (m, 2H, H-7,9); LC-MS, m/z = 393 [M+1]; Anal. calcd. for C22H15F3N4: C, 67.34; Н, 3.85; N, 14.28; 
Found: C, 67.36; Н, 3.90; N, 14.31.
2-Phenyl-5-(3-(trifluoromethyl)phenyl-5,6-dihydro- 
[1,2,4]triazolo[1,5-c]quinazoline (2.9). Yield – 86.7%. M.p. – 168-170°C; 1H NMR (400 MHz, dmso_d6+ССl4) 
δ 8.06 (d, J = 6.7 Hz, 1H, H-2,6 Ph), 7.84 (m, 1H, H-2 3-CF3Ph, H-10), 7.65 (s, 1H, H-6), 7.57 (m, 3H, H-4,6 3-CF3Ph, H-4 Ph), 7.46-7.32 (m, 2H, H-5 3-CF3Ph, 
H-3,5 Ph), 7.24 (t, J = 7.1 Hz, 1H, H-8), 7.00 (s, 1H, 
H-5), 6.91 (d, J = 7.9 Hz, 1H, H-7), 6.84 (t, J = 7.4 Hz, 1H, H-9); LC-MS, m/z = 393 [M+1]; Anal. calcd. for C22H15F3N4: C, 67.34; Н, 3.85; N, 14.28; Found: C, 67.33; 
Н, 3.87; N, 14.26.
2-Phenyl-5-(4-(trifluoromethyl)phenyl)-5,6-dihyd- 
ro-[1,2,4]triazolo[1,5-c]quinazoline (2.10). Yield – 55.1%. M.p. – 166-168°C; 1H NMR (400 MHz, dmso_d6+ССl4) 
δ 8.05 (d, J = 7.0 Hz, 2H, H-2,6 Ph), 7.81 (d, J = 7.6 Hz, 
1H, H-10), 7.66 (d, J = 7.8 Hz, 1H, H-2,6 4-CF3Ph), 7.62- 
7.53 (m, J = 8.5 Hz, 3H, H-3,5 4-CF3Ph, H-6), 7.46-
7.32 (m, 3H, H-3,4,5 Ph), 7.23 (t, J = 7.5 Hz, 1H, H-8), 
6.99 (s, 1H, H-5), 6.89 (d, J = 7.9 Hz, 1H, H-7), 6.83 (t, 
J = 7.4 Hz, 1H, H-9); 1H NMR (400 MHz, CDCl3) δ 8.09 
(d, J = 6.4 Hz, 2H, H-2,6 Ph), 8.00 (d, J = 7.6 Hz, 1H, 
H-10), 7.59 (d, J = 7.7 Hz, 2H, H-2,6 PhCF3), 7.49 (d, J = 7.9 Hz, 2H, H-3,5 PhCF3), 7.44-7.34 (m, 3H, H-3,4,5 
Ph), 7.27 (m, 2H, H-8, CHCl3), 6.97 (t, J = 7.4 Hz, 1H, 
H-9), 6.78-6.73 (m, 2H, H-7, H-5), 4.76 (s, 1H, H-6); 13C NMR (100 MHz, CDCl3) δ 158.12 (C-2), 145.47 
(C-6a), 137.48 (C-1, PhCF3), 136.21 (C-10b), 127.19, 126.01, 124.66, 123.76, 122.46, 121.79, 121.21, 120.32, 
115.74, 110.17, 106.80 (C-10a), 67.11 (C-5); LC-MS, 
m/z = 393 [M+1]; Anal. calcd. for C22H15F3N4: C, 67.34; 
Н, 3.85; N, 14.28; Found: C, 67.34; Н, 3.85; N, 14.28.
2-Phenyl-5-(2-chlorophenyl)-5,6-dihydro-[1,2,4]tri- 
azolo[1,5-c]quinazoline (2.11). Yield – 92.7%. M.p. – 204-206°C; 1H NMR (400 MHz, DMSO_D6+CCl4) δ 
8.04 (t, J = 7.1 Hz, 1H, H-2,6 Ph), 7.84 (d, J = 7.5 Hz, 
1H, H-10), 7.49 (d, J = 7.8 Hz, 1H, H-3 2-ClPh), 7.45-
7.31 (m, 5H, H-3,4,5 Ph, H-5 2-ClPh, H-6,), 7.28 (t, J = 7.6 Hz, 1H, H-8), 7.25-7.16 (m, 3H, H-4,6 2-ClPh, H-5), 
6.92-6.78 (m, 2H, H-7, 9); LC-MS, m/z = 359 [M+1], 361 [M+3]; Anal. calcd. for C21H15ClN4: C, 70.29; Н, 4.21; 
N, 15.61; Found: C, 70.33; Н, 4.24; N, 15.63.
2-Phenyl-5-(3-chlorophenyl)-5,6-dihydro-[1,2,4]tri- 
azolo[1,5-c]quinazoline (2.12). Yield – 94.9%. M.p. – 150-152°C; 1H NMR (400 MHz, dmso_d6+ССl4) δ 8.07 
(d, J = 7.0 Hz, 1H, H-2,6 Ph), 7.82 (d, J = 7.4 Hz, 1H, 
H-10), 7.54 (s, 1H, H-6), 7.47 (s, 1H, H-2 3-ClPh), 7.45-
7.31 (m, 4H, H-3,5 Ph, H-4,5 3-ClPh), 7.31-7.17 (m, 
3H, H-4 Ph, H-6 3-ClPh, H-8), 6.94-6.86 (m, 2H, H-5, 7), 
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6.83 (t, J = 7.5 Hz, 1H, H-9); LC-MS, m/z = 359 [M+1], 361 [M+3]; Anal. calcd. for C21H15ClN4: C, 70.29; Н, 4.21; 
N, 15.61; Found: C, 70.26; Н, 4.19; N, 15.59.
2-Phenyl-5-(4-chlorophenyl)-5,6-dihydro-[1,2,4]tri- 
azolo[1,5-cquinazoline (2.13). Yield – 84.3%. M.p. – 172-174°C; 1H NMR (400 MHz, dmso_d6+ССl4) δ 8.05 
(d, J = 7.3 Hz, 1H, H-2,6 Ph), 7.80 (d, J = 7.3 Hz, 1H, 
H-10), 7.48 (s, 1H, H-6), 7.46-7.26 (m, 7H, H-2,3,5,6 
4-ClPh, H-3,4,5 Ph), 7.22 (t, J = 7.5 Hz, 1H, H-8), 6.93-
6.86 (m, 2H, H-5, 7), 6.82 (t, J = 7.4 Hz, 1H, Н-9); LC-MS, m/z = 359 [M+1], 361 [M+3]; Anal. calcd. for C21H15ClN4: C, 70.29; Н, 4.21; N, 15.61; Found: C, 
70.31; Н, 4.23; N, 15.60.
5-(2-Bromophenyl)-2-phenyl-5,6-dihydro-[1,2,4]tri- 
azolo[1,5-c]quinazoline (2.14). Yield – 93.0%. M.p. – 209-210°C; 1H NMR (400 MHz, dmso_d6+ССl4) δ 8.04 
(d, J = 6.6 Hz, 2H, Р-2,6 Ph), 7.84 (d, J = 7.0 Hz, 1H, 
H-10), 7.67 (d, J = 6.7 Hz, 1H, H-3 2-BrPh), 7.47-7.16 
(m, 5H, H-6, H-3,4,5 Ph, H-4,5,6 2-BrPh, H-5), 6.95-
6.79 (m, 2H, H-7, 9); LC-MS, m/z = 404 [M+1]; Anal. calcd. for C21H15BrN4: C, 62.54; Н, 3.75; N, 13.89; 
Found: C, 62.56; Н, 3.78; N, 13.90.
5-(3-Bromophenyl)-2-phenyl-5,6-dihydro-[1,2,4]tri- 
azolo[1,5-c]quinazoline (2.15). Yield – 84.6%. M.p. – 174-176; LC-MS, m/z = 404 [M+1]; Anal. calcd. for C21H15BrN4: C, 62.54; Н, 3.75; N, 13.89; Found: C, 62.52; 
Н, 3.73; N, 13.87.
2-(2-Chlorophenyl)-5-(2-fluorophenyl)-5,6-dihydro- 
[1,2,4]triazolo[1,5-c]quinazoline (2.16). Yield – 93.3%. M.p. – 128-130°C; 1H NMR (400 MHz, dmso_d6+ССl4) 
δ 7.89 (m, 1H, H-6 2-ClPh), 7.81 (d, J = 7.2 Hz, 1H, 
H-10), 7.51-7.31 (m, 5H, H-3,5 2-FPh, H-3,5 2-ClPh, 
H-6), 7.29-7.06 (m, 5H, H-4 2-ClPh, H-4,6 2-FPh, H-5, 
H-8), 6.94-6.76 (m, 2H, H-7, H-9); LC-MS, m/z = 377 [M+1], 379 [M+3]; Anal. calcd. for C21H14ClFN4: C, 66.94; 
Н, 3.74; N, 14.87; Found: C, 66.92; Н, 3.70; N, 14.84.
2-(2-Chlorophenyl)-5-(2-methylphenyl)-5,6-di- 
hydro-[1,2,4]triazolo[1,5-c]quinazolines (2.17). Yield – 93.9%. M.p. – 197-199°C; 1H NMR (400 MHz, dmso_d6+ССl4) δ 7.89-7.82 (m, 1H, H-6 2-ClPh), 7.79 (d, J = 7.3 Hz, 1H, H-10), 7.49-7.40 (m, 1H, H-3 2-ClPh), 
7.40-7.14 (m, 8H, H-6, H-3,4,5,6 2-CH3Ph, H-4,5 2ClPh, 
H-8), 7.05 (s, 1H, H-5), 6.88 (d, J = 7.9 Hz, 1H, H-7), 
6.80 (t, J = 7.2 Hz, 1H, H-9), 2.50 (s, 3H, -CH3); LC-MS, 
m/z = 373 [M+1], 375 [M+3] Anal. calcd. for C22H17ClN4: 
C, 70.87; Н, 4.60; N, 15.03; Found: C, 70.91; Н, 4.63; N, 15.05.
5-(2-Methylphenyl)-2-(3-fluorophenyl)-5,6-dihyd- 
ro-[1,2,4]triazolo[1,5-c]quinazoline (2.18). Yield – 62.1%. M.p. – 225-227°C; 1H NMR (400 MHz, dmso_d6+ССl4) 
δ 7.83 (m, 2H, H-2,6 3-FPh), 7.71 (d, J = 9.4 Hz, 1H, H-10), 
7.53 (m, 1H, H-6), 7.49-7.34 (m, 2H, H-4,5 3-FPh), 
7.34-7.14 (m, 2H), 7.14-7.05 (t, 1H, H-8), 7.03 (s, 1H, 
H-5), 6.86 (d, J = 7.8 Hz, 1H, H-7), 6.81 (t, J = 7.3 Hz, 
1H, H-9), 2.52 (s, 1H, -CH3); Anal. calcd. for C22H17FN4: 
C, 74.14; Н, 4.81; N, 15.72; Found: C, 74.16; Н, 4.84; N, 15.73.
the general method for the synthesis of 5-r1-
2-aryl-[1,2,4]triazolo[1,5-c]quinazolines (3.1-3.14) 
Method А. To the solution of 10 mmol of the cor- responding {2-[3-aryl-1H-1,2,4-triazol-5-yl]phenyl} 
amine (1.1-1.9) in 10 ml of glacial acetic acid add 
10 mmol of aliphatic or aromatic aldehyde. Reflux the mixture obtained for 8 h. Then cool the mixture and pour into the saturated solution of sodium ace- tate. Filter the precipitate formed and dry. In case of 
insufficient purity recrystallize the compounds ob- tained from methanol.
Method B. To the solution of 10 mmol of the cor- responding 5-R1-2-aryl-5,6-dihydro[1,2,4]triazolo [1,5-c]quinazoline (2.2, 2.4, 2.8, 2.10) in 10 ml of wa- 
ter – dioxane mixture (1:3) add dropwise 11 mmol of bromine or potassium permanganate at 40oC. Re- 
flux the mixture obtained for 8 h. Then cool the mix-ture and pour into the saturated solution of sodium acetate. Filter the precipitate formed and dry. In case 
of insufficient purity recrystallize the compounds ob- tained from propanol-1.
Method C. To the solution of 10 mmol of {2-[3- phenyl-1H-1,2,4-triazol-5-yl]phenyl}amine (5.1) in 
10 ml of glacial acetic acid add 0.9 g. (11 mmol) of sodium acetate. Cool the mixture obtained to 3-5°С and add dropwise 11 mmol of the corresponding acyl 
halide while stirring. Then reflux the reaction mixtu- 
re for 6 h. After refluxing cool the mixture, and evap-orate the solvent under vacuum. Then add 10 ml of 
methanol, filter the precipitate and dry. Compounds 
3.1-3.14 that were obtained according to methods A, B, C had the same physicochemical constants and spectral characteristics.
The compounds (3.1-3.14) synthesized are white crystalline powders, insoluble in water, soluble in alcohols, dioxane and DMF. 
5-Isopropyl-2-(4-methoxyphenyl)-[1,2,4]triazolo 
[1,5-c]quinazoline (3.1). Yield– 48.7 (Method A), 86.8% 
(Method В). M.p. – 150-152°C; 1H NMR (400 MHz, dmso_d6+ССl4) δ 8.50 (d, J = 7.9 Hz, 1H, H-10), 8.24 
(d, J = 6.9 Hz, 2H, H-2,6 PhOCH3-4), 8.01 (d, J = 7.8 Hz, 
1H, H-7), 7.83 (t, 1H, H-9), 7.73 (d, J = 7.6 Hz, 1H, H-8), 
7.04 (d, J = 7.0 Hz, 2H, H-3,5 PhOCH3-4 ), 4.04 (dt, 
J = 14.7, 7.4 Hz, 1H, (CH3)2CH-), 3.89 (s, 1H, OCH3), 
1.56 (s, 6H, (CH3)2CH-); LC-MS, m/z = 319 [M+1]; Anal. calcd. for C19H18N4O: C, 71.68; Н, 5.70; N, 17.69; 
Found: C, 71.69; Н, 5.75; N, 17.67.
5-Isobutyl-2-(3-fluorophenyl)-[1,2,4]triazolo[1,5-c] 
quinazoline (3.2). Yield – 60.3% (Method A), 91.8% 
(Method Б). M.p. – 129-131°C; 1H NMR (400 MHz, dmso_d6+ССl4) δ 8.50 (d, J = 7.6 Hz, 1H, H-10), 8.15 
(d, J = 7.6 Hz, 1H, H-7), 8.03-7.97 (m, 2H, H-2,6 PhF-
3), 7.87 (m, 1H, H-9), 7.75 (m, 1H, H-8), 7.56 (m, 1H, 
H-5 PhF-3), 7.26 (t, J = 8.1 Hz, 1H, H-4 PhF-3), 3.27 
(d, J = 6.0 Hz, 1H, -СН2СН(СН3)2), 2.69-2.56 (m, 1H, 
-СН2СН(СН3)2), 1.14 (s, J = 5.3 Hz, 6H, -СН2СН(СН3)2); LC-MS, m/z = 321 [M+1], 323 [M+3]; Anal. calcd. 
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71.20; Н, 5.31; N, 17.46.
5-Cyclopentyl-2-(4-fluorophenyl)-[1,2,4]triazolo 
[1,5-c]quinazoline (3.3). Yield – 39.5% (Method A). M.p. – 196-198°C; 1H NMR (400 MHz, dmso_d6+ССl4) 
δ 8.49 (d, J = 7.7 Hz, 1H, H-10), 8.40-8.31 (m, 2H, 
H-2,6 PhF-4), 7.96 (d, J = 7.7 Hz, 1H, H-7), 7.87 (t, J = 7.3 Hz, 1H, H-9), 7.72 (t, J = 6.9 Hz, 1H, H-8), 7.33-
7.22 (m, 2H, H-3,5 PhF-4), 4.13 (dt, J = 13.7, 6.7 Hz, 
1H, H-1 cyclopenthyl), 2.32 (dd, J = 17.0, 9.4 Hz, 2H, 
H-2,5 cyclopenthyl), 2.23-2.11 (m, 2H, H-2,5 cyclo- 
penthyl), 2.02-1.88 (m, 2H, H-3,4 cyclopenthyl), 1.83 
(dd, J = 13.7, 12.0 Hz, 2H, H-3,4 cyclopenthyl); LC-MS, 
m/z = 333 [M+1], 335 [M+3]; Anal. calcd. for C20H17FN4: 
C, 72.27; Н, 5.16; N, 16.86; Found: C, 72.31; Н, 5.19; N, 16.88.
2-(3-(Trifluoromethyl)phenyl)-5-cyclopentyl- 
[1,2,4]triazolo[1,5-c]quinazoline (3.4). Yield – 49.9% 
(Method A). M.p. – 138-140°C; 1H NMR (400 MHz, dmso_d6+ССl4) δ 8.58 (m, 2H, H-2, 6 PhCF3-3), 8.53 (d, 
J = 8.0 Hz, 1H, H-10), 7.98 (d, J = 8.0 Hz, 1H, H-7), 7.87 
(t, 1H, H-9), 7.84-7.71 (m, 3H, H-8, H-4, 5 PhCF3-3), 
4.22 (qun, J = 15.9, 7.8 Hz, 1H, H-1 cyclopenthyl), 2.39- 
2.25 (m, 2H, H-2,5 cyclopenthyl), 2.25 – 2.12 (m, 2H, 
H-2,5 cyclopenthyl), 2.02-1.90 (m, 2H, H-3,4 cyclo- 
penthyl), 1.90-1.79 (m, 2H, H-3,4 cyclopenthyl); Anal. calcd. for C21H17F3N4: C, 65.96; Н, 4.48; N, 14.65; Found: 
C, 66.01; Н, 4.53; N, 14.68.
2-(3-Methoxyphenyl)-5-cyclopentyl-[1,2,4]triazolo 
[1,5-c]quinazoline (3.5). Yield – 70.1% (Method A). M.p. – 149-151°C; 1H NMR (400 MHz, dmso_d6) δ 
8.52 (d, J = 7.8 Hz, 1H, H-10), 7.96 (d, J = 8.2 Hz, 1H, H-6 PhOCH3-3), 7.90 (d, J = 7.6 Hz, 1H, H-7), 7.88-7.79 
(m, 2H, H-2, 5 PhOCH3-3), 7.72 (t, J = 7.5 Hz, 1H, H-9), 
7.42 (t, J = 7.9 Hz, 1H, H-8), 7.04 (d, J = 8.0 Hz, 1H, H-4 PhOCH3-3), 4.22-4.08 (m, 1H, H-1 cyclopenthyl), 
3.93 (s, 3H, OCH3), 2.31 (dt, J = 11.9, 8.1 Hz, 2H, H-2,5 
cyclopenthyl), 2.19 (dt, J = 20.2, 7.3 Hz, 2H, H-2,5 cy-
clopenthyl), 2.01-1.90 (m, 2H, H-3,4 cyclopenthyl), 
1.90-1.76 (m, 2H, H-3,4 cyclopenthyl); LC-MS, m/z= 345 [M+1], 347 [M+3]; Anal. calcd. for C21H20N4О: C, 
73.23; Н, 5.85; N, 16.27; Found: C, 73.20; Н, 5.83; N, 16.24.
5-Cyclohexyl-2-phenyl-[1,2,4]triazolo[1,5-c]quinazo- 
line (3.6). Yield – 85.4% (Method B). M.p. – 196-198°C; 1H NMR (400 MHz, dmso_d6+ССl4) δ 8.51 (d, J = 7.8 Hz, 
1H, H-10), 8.34 (d, J = 6.5 Hz, 2H, H-2,6 Ph), 7.96 (d, 
J = 7.8 Hz, 1H, H-7), 7.85 (t, J = 7.3 Hz, 1H, H-9), 7.72 
(t, J = 7.0 Hz, 1H, H-8), 7.53 (m, 3H, H-3,4,5 Ph), 3.77 
(t, 1H, H-1 cyclohexyl), 2.22 (d, J = 12.7 Hz, 2H, H-2, 
6 cyclohexyl), 2.00 (d, 2H, H-2, 6 cyclohexyl), 1.93-1.78 
(m, 4H, H-3, 5 cyclohexyl), 1.70-1.55 (m, 2H, H-4 cyc- lohexyl) ; LC-MS, m/z = 329 [M+1], 331 [M+3]; Anal. calcd. for C21H20N4: C, 76.80; Н, 6.14; N, 17.06; Found: 
C, 76.78; Н, 6.12; N, 17.04.
2-(3-Methoxyphenyl)-5-cyclohexyl-[1,2,4]triazolo 
[1,5-c]quinazoline (3.7). Yield – 43.0% (Method A). M.p. – 176-177°C; 1H NMR (400 MHz, dmso_d6) δ 
8.52 (d, J = 7.8 Hz, 1H, H-10), 7.96 (d, J = 8.1 Hz, 1H, 
H-7), 7.90 (d, J = 7.5 Hz, 1H, H-6 PhOCH3-3), 7.88- 
7.77 (m, 2H, H-9, H-2 PhOCH3-3), 7.72 (t, J = 7.4 Hz, 
1H, H-8), 7.42 (t, J = 7.9 Hz, 1H, H-5 PhOCH3-3), 7.04 
(d, J = 8.0 Hz, 1H, H-4 PhOCH3-3), 3.94 (s, 3H, -OCH3), 
3.76 (t, J = 8.0 Hz, 1H, H-1 cyclohexyl), 2.22 (dd, J = 
12.0, 2H, H-2, 6 cyclohexyl), 1.99 (d, 2H, H-2, 6 cy-
clohexyl), 1.84-1.80 (m, 2H, H-3, 5 cyclohexyl), 1.71-
1.51 (m, 2H, H-3, 5 cyclohexyl), 1.42 (m, 2H, H-4 cyc- lohexyl) ; LC-MS, m/z = 359 [M+1], 361 [M+3]; Anal. calcd. for C22H22N4O: C, 73.72; Н, 6.19; N, 15.63; Found: 
C, 73.74; Н, 6.21; N, 15.65.
5-(4-Methylphenyl)-2-phenyl-[1,2,4]triazolo[1,5-c] 
quinazoline (3.8). Yield – 94.6% (Method A), 67.8% 
(Method C). M.p. – 183-185°C; 1H NMR (400 MHz, dmso_d6+ССl4) δ 8.61-8.51 (m, 3H, H-2,6 PhCH3-4, 
H-10), 8.33 (d, J = 6.1 Hz, 2H, H-2,6 Ph), 8.05 (d, J = 7.9 Hz, 1H, H-7), 7.88 (t, J = 7.1 Hz, 1H, H-9), 7.75 (t, 
J = 7.1 Hz, 1H, H-8), 7.52 (m, 3H, H-3, 4, 5 Ph), 7.41 
(d, J = 7.4 Hz, 2H, H-3,5 PhCH3-4), 2.50 (s, 1H, -CH3) ; LC-MS, m/z = 337 [M+1], 339 [M+3]; Anal. calcd. for C22H16N4: C, 78.55; Н, 4.79; N, 16.66; Found: C, 78.56; 
Н, 4.81; N, 16.67.
5-(4-Bromophenyl)-2-phenyl-[1,2,4]triazolo[1,5-c] 
quinazoline (3.9). Yield – 41.8% (Method A), 78.3% 
(Method C). M.p. – 217-219°C; 1H NMR (400 MHz, dmso_d6+ССl4) δ 8.65 (d, J = 7.8 Hz, 2H, H-2,6 Ph), 
8.59 (d, J = 7.8 Hz, 1H, H-10), 8.35 (d, J = 7.0 Hz, 2H, 
H-2,6 PhBr-4), 8.10 (d, J = 7.8 Hz, 1H, H-7), 7.92 (t, 
J = 7.7 Hz, 1H, H-9), 7.85-7.77 (m, 3H, H-8, H-3,5 
PhBr-4), 7.60-7.48 (m, 3H, H-3,4,5 Ph); Anal. calcd. for C21H13BrN4: C, 62.86; Н, 3.27; N, 13.96; Found: C, 
62.88; Н, 3.31; N, 14.01.
2-(3-(Trifluoromethyl)phenyl)-5-(3-fluorophenyl)- 
[1,2,4]triazolo[1,5-c]quinazoline (3.10). Yield – 39.7% 
(Method A). M.p. – 148-150°C; 1H NMR (400 MHz, dmso_d6+ССl4) δ 8.65-8.50 (m, 5H, Н-2,6 PhF-3, 
Н-2,6 PhCF3-3, H-10), 8.42 (d, J = 7.8 Hz, 1H, Н-7), 
8.10 (m, 1H, H-9), 7.94 (dd, J = 15.6, 7.8 Hz, 1H, H-5 PhCF3-3), 7.88-7.73 (m, 2H, H-8, H-4 PhCF3-3), 7.68 
(dd, J = 14.6, 7.2 Hz, 1H, H-5, PhF-3), 7.44 (t, J = 7.9 Hz, 1H, H-4 PhF-3); LC-MS, m/z = 409 [M+1], 411 [M+3]; Anal. calcd. for C22H12F4N4: C, 64.71; Н, 2.96; N, 13.72; 
Found: C, 64.72; Н, 2.99; N, 13.75.
2-(3-Methylphenyl)-5-(3-fluorophenyl)-[1,2,4]tri- 
azolo[1,5-c]quinazoline (3.11). Yield – 41.6% (Me- thod A). M.p. – 141-143°C; 1H NMR (400 MHz, dmso_d6+ССl4) δ 8.99 (m, 2H, H-2 PhCF3-3, H-10), 8.60 (d, J = 7.3 Hz, 1H, H-7), 8.22 (d, J = 7.5 Hz, 2H, H-4, 6 PhCF3-3), 
8.14 (d, J = 7.8 Hz, 1H, H-6 PhCH3-3), 8.03-7.78 (m, 3H, H-9, H-5 PhCF3-3, H-5 PhCH3-3), 7.35 (m, 2H, H-8, H-4 PhCH3-3), 2.47 (s, 2H) ; LC-MS, m/z = 405 [M+1], 406 [M+2]; Anal. calcd. for C23H15F3N4: C, 68.31; Н, 
3.74; N, 13.85; Found: C, 68.29; Н, 3.72; N, 13.81.
2-(3-Methoxyphenyl)-5-(4-chlorophenyl)-[1,2,4]tri- 
azolo[1,5-c]quinazoline (3.12). Yield – 37.9% (Method A), 
61.6% (Method C). M.p. – 217-219°C; 1H NMR (400 MHz, 
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ISSN 2308-8303dmso_d6+ССl4) δ 8.68 (d, J = 8.0 Hz, 2H, H-2,6 РhCl-
4), 8.57 (d, J = 7.7 Hz, 1H, Н-10), 8.07 (d, J = 8.0 Hz, 
1H, Н-7), 7.91-7.87 (m, 2H, H-9, H-6 PhOCH3-3), 
7.85-7.76 (m, 2H, H-8, H-2 PhOCH3-3), 7.64 (d, J = 8.2 Hz, 2H, H-3,5 РhCl-4), 7.47 (t, J = 7.4 Hz, 1H, H-5 PhOCH3-3), 7.04 (d, J = 7.4 Hz, 1H, H-4 PhOCH3-3), 
3.92 (s, 3H, -OCH3); LC-MS, m/z = 387 [M+1], 389 [M+3]; Anal. calcd. for C22H15ClN4O: C, 68.31; Н, 3.91; 
N, 14.48; Found: C, 68.34; Н, 3.93; N, 14.51.
2-Phenyl-5-(2-(trifluoromethyl)phenyl)-[1,2,4]tri- 
azolo[1,5-c]quinazoline (3.13). Yield – 43.8% (Method B). M.p. – 192-194°C; 1H NMR (400 MHz, CDCl3) δ 8.66 
(d, J = 7.9 Hz, 1H, H-10), 8.26 (н.р. d, 2H, H-2,6 Ph), 
8.10 (d, J = 8.2 Hz, 1H, H-7), 7.94-7.83 (m, 2H, H-9, H-6 PhCF3-2), 7.82-7.71 (m, 4H, H-8, H-3,4,5 PhCF3-2), 
7.48-7.36 (m, 3H, H-3,4,5 Ph); 13C NMR (100 MHz, CDCl3) δ 159.60 (C-2), 147.26 (C-5), 137.95 (C-6a), 
127.39 (C-10b), 127.08, 126.26, 125.95, 125.65, 125.33, 124.16, 124.14, 123.87, 123.71, 122.93, 122.39, 121.85, 
120.22, 119.10, 112.93 (C-10a); Anal. calcd. for C22H13F3N4: 
C, 67.69; Н, 3.36; N, 14.35; Found: C, 67.71; Н, 3.39; N, 14.36.
2-Phenyl-5-(4-(trifluoromethyl)phenyl)-[1,2,4]tri- 
azolo[1,5-c]quinazoline (3.14). Yield – 57.3% (Method B). M.p. – 205-207°C; 1H NMR (400 MHz, CDCl3) δ 8.80 
(d, J = 8.1 Hz, 2H, H-2,6 PhCF3-4), 8.64 (d, J = 7.9 Hz, 
1H, H-10), 8.38 (d, J = 5.8 Hz, 1H, H-2, 6 Ph), 8.12 (d, 
J = 8.2 Hz, 1H, H-7), 7.93-7.82 (m, 3H, H-3,5 PhCF3-4, 
H-9), 7.75 (t, J = 7.5 Hz, 1H, H-8), 7.59-7.46 (m, 3H, H-3,4,5 Ph); 13C NMR (100 MHz, CDCl3) δ 159.48 (C-2), 
148.14 (C-5), 140.11 (C-6a), 137.95 (C-10b), 130.34, 127.47, 126.12, 125.87, 125.27, 124.14, 124.03, 124.00, 
122.90, 120.57, 120.53, 120.50, 119.10, 112.77 (С-10a); LC-MS, m/z = 391[M+1], 393 [M+3]; Anal. calcd. for C22H13F3N4: C, 67.69; Н, 3.36; N, 14.35; Found: C, 67.68; 
Н, 3.35; N, 14.35.
Conclusions
The reaction of [2-(3-aryl-1H-1,2,4-triazole-5-yl)phenyl]amines with aliphatic and aromatic aldehy- 
des is a suitable method for the synthesis of 5-(al- kyl-, cycloalkyl-, aryl-)-2-aryl-5,6-dihydro[1,2,4]triazolo [1,5-с]quinazolines. These compounds are oxidizable; therefore, the inert gas atmosphere is the necessary condition for the [5+1]-cyclocondensation process. 
On the other hand, this property allows to use 5- (al- kyl-, cycloalkyl-, aryl-)-2-aryl-5,6-dihydro[1,2,4]tri- azolo[1,5-с]quinazolines as the initial compounds for the synthesis of their aromatic analogues. The con-venient synthetic procedures for compounds 2 and 
3 have been proposed, and the mechanism of these transformations has been discussed.
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